|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Effectiveness of very low-volume preparation for colonoscopy:A prospective, multicenter observational study显示文摘BACKGROUND The effectiveness of colonoscopy strictly depends on adequate bowel cleansing.Recently,a 1 L polyethylene glycol plus ascorbate(PEG-ASC)solution(Plenvu;Norgine,Harefield,United Kingdom)has been introduced on the evidence of three phase-3 randomized controlled trials,but it had never been tested in the real-life.AIM To assess the effectiveness and tolerability of the 1 L preparation compared to 4 L and 2 L-PEG solutions in a real-life setting.METHODS All patients undergoing a screening or diagnostic colonoscopy after a 4,2 or 1 L PEG preparation,were consecutively enrolled in 5 Italian centers from September 2018 to February 2019.The primary endpoints of the study were the assessment of bowel cleansing success and high-quality cleansing of the right colon.The secondary endpoints were the evaluation of tolerability,adherence and safety of the different bowel preparations.Bowel cleansing was assessed through the Boston Bowel Preparation Scale.Adherence was defined as consumption of at least 75%of each dose,while tolerability was evaluated through a semiquantitative scale.Safety was systematically monitored through adverse events reporting.RESULTS Overall,1289 met the inclusion criteria and were enrolled in the study.Of these,490 patients performed a 4 L-PEG preparation(Selgesse^■),566 a 2 L-PEG cleansing(Moviprep^■or Clensia^■)and 233 a 1 L-PEG preparation(Plenvu^■).Bowel cleansing by Boston Bowel Preparation Scale was 6.5±1.5 overall and 6.3±1.5,6.2±1.5,7.3±1.5(P<0.001)in the subgroups of 4 L,2 L and 1 L-PEG preparation,respectively.Cleansing success was achieved in 72.4%,74.1%and 90.1%(P<0.001),while a high-quality cleansing of the right colon in 15.9%,12.0%and 41.4%(P<0.001)for 4 L,2 L and 1 L-PEG preparation groups,respectively.The 1 L preparation was the most tolerated compared to the 2 and 4 L-PEG solutions in the absence of serious adverse events within any of the three groups.Multiple regression models confirmed 1 L PEG-ASC preparation as an independent predictor of overall cleansing success,high-quality cleansing of the right colon and of tolerability.CONCLUSION This study supports the effectiveness and tolerability of 1 L PEG-ASC,also showing it is an independent predictor of overall cleansing success,high-quality cleansing of the right colon and of tolerability. | Marcello Maida Emanuele Sinagra Gaetano Cristian Morreale Sandro Sferrazza Giuseppe Scalisi Dario Schillaci Marco Ventimiglia Fabio Salvatore Macaluso Giovanni Vettori Giuseppe Conoscenti Concetta Di Bartolo Serena Garufi Domenico Catarella Michele Manganaro Clara Maria Virgilio Salvatore Camilleri | 2020 | World Journal of Gastroenterology2020，26，16： | 2 |
| 2 | Metastatic pancreatic cancer: Is there a light at the end of the tunnel?显示文摘Due to extremely poor prognosis,pancreatic cancer(PDAC)represents the fourth leading cause of cancerrelated death in Western countries.For more than a decade,gemcitabine(Gem)has been the mainstay of first-line PDAC treatment.Many efforts aimed at improving single-agent Gem efficacy by either combining it with a second cytotoxic/molecularly targeted agent or pharmacokinetic modulation provided disappointing results.Recently,the field of systemic therapy of advanced PDAC is finally moving forward.Polychemotherapy has shown promise over single-agent Gem:regimens like PEFG-PEXG-PDXG and GTX provide significant potential advantages in terms of survival and/or disease control,although sometimes at the cost of poor tolerability.The PRODIGE 4/ACCORD 11 was the first phaseⅢtrial to provide unequivocal benefit using the polychemotherapy regimen FOLFIRINOX;however the less favorable safety profile and the characteristics of the enrolled population,restrict the use of FOLFIRINOX to young and fit PDAC patients.The nanoparticle albumin-bound paclitaxel(nab-Paclitaxel)formulation was developed to overcome resistance due to the desmoplastic stroma surrounding pancreatic cancer cells.Regardless of whether or not this is its main mechanisms of action,the combination of nabPaclitaxel plus Gem showed a statistically and clinically significant survival advantage over single agent Gem and significantly improved all the secondary endpoints.Furthermore,recent findings on maintenance therapy are opening up potential new avenues in the treatment of advanced PDAC,particularly in a new era in which highly effective first-line regimens allow patients to experience prolonged disease control.Here,we provide an overview of recent advances in the systemic treatment of advanced PDAC,mostly focusing on recent findings that have set new standards in metastatic disease.Potential avenues for further development in the metastatic setting and current efforts to integratenew effective chemotherapy regimens in earlier stages of disease(neoadjuvant,adjuvant,and multimodal approaches in both resectable and unresectable patients)are also briefly discussed. | Vanja Vaccaro Isabella Sperduti Sabrina Vari Emilio Bria Davide Melisi Carlo Garufi Carmen Nuzzo Aldo Scarpa Giampaolo Tortora Francesco Cognetti Michele Reni Michele Milella | 2015 | World Journal of Gastroenterology2015，21，16： | 2 |
| 3 | Hepatic arterial infusion (HAI) of cisplatin and systemic fluorouracil in the treatment of unresectable colorectal liver metastases显示文摘 | Mancini R Tedesco M Garufi C | 2003 | Anticancer Res2003，23，2： | 1 |
| 4 | New endoscopy advances to refine adenoma detection rate for colorectal cancer screening:None is the winner显示文摘Colorectal cancer(CRC) is the third most common cancer in males and second in females, and globally the fourth cause for cancer death worldwide. Oncological screening of CRC has a major role in the management of the disease and it is mostly performed by colonoscopy. Anyway, effectiveness of endoscopic screening for CRC strictly depends on adequate detection and removal of potentially precancerous lesions, and accuracy of colonoscopy in detection of adenomas is still suboptimal. For this reason, several technological advances have been implemented in order to improve the diagnostic sensitivity of colonoscopy in adenoma detection. Among these:(1) Visual technologies such as chromoendoscopy and narrow band imaging;(2) optical innovation as high definition endoscopy, full-spectrum endoscopy or Third Eye Retroscope; and(3) mechanical advances as Cap assisted colonoscopy, Endocuff, Endoring and G-Eye endoscope. All these technologies advances have been tested over time by clinical studies with mixed results. Which of them is more likely to be successful in the next future? | Marcello Maida Salvatore Camilleri Michele Manganaro Serena Garufi Giuseppe Scarpulla | 2017 | World Journal of Gastrointestinal Oncology2017，9，10： | 1 |
| 5 | Protective effect of Capparis spinosa on chondrocytes 显示文摘 | Panico AM Cardile V Garufi F | 2005 | Life Sci2005，77，20： | 1 |
| 6 | Protective effect of Capparis spinosa on chondrocytes显示文摘 | PANICO A M CARDILE V GARUFI F | 2005 | Life Sciences2005，77，： | 1 |
| 7 | Quality of life and chronotherapy显示文摘 | Pugliese P Garufi C Perrone M | 2002 | CBI2002，19，1： | 1 |
| 8 | A phase Ⅱ study of irinotecan plus chronomodulated oxaliplatin,5-fluorouracil and folinic acid in advanced colorectal cancer patients显示文摘 | Garufi C Bria E Vanni B | 2003 | Br J Cancer2003，89，： | 1 |
| 9 | Protective effect of Capparis spinosa on chondrocytes显示文摘 | Panico AM Cardile V Garufi F | 2005 | Life Sciences2005，77，： | 1 |
| 10 | POCHER (Pre Operative Chemo- therapy for Hepatic Resection) study with cetuximab (C-225) plus chronomodulated (chrono) CPT-11/5-fluorouracil ( 5-Fu ) /leuco- vorin ( FA)/oxaliplatin (L-OHP) (CPT-FFL) in colorectal liver metastases (CLM) 显示文摘 | Garufi C Torsello A Tumulo S | 2012 | ASCO G12012，7，5： | 1 |
| 11 | Protective effect of Capparis spi- nosa on chondrocytes显示文摘 | Panico A M Cardile V Garufi F | 2005 | Life Sciences2005，77，： | 1 |
| 12 | Protective effect of Capparis spinosa on chondrocytes显示文摘 | PANICO A M CARDILE V GARUFI F | 2005 | Life Sciences2005，77，20： | 1 |
| 13 | ESAT-6-like protein secretion in Bacillus anthracis 显示文摘 | Garufi G Butler E Missiakas D | 2008 | J Bacteriol2008，190，70： | 1 |
| 14 | A phase Ⅱ study of irinotecan plus chronomodulated oxaliplatin,5-fluorouracil and folinic acid in advanced colorectal cancer patients显示文摘 | Garufi C Bria E Vanni B | 2003 | Br J Cancer2003，89，10： | 1 |
| 15 | P53 and bcl - 2 in colorectal cancer arising in patients under 40 years of age: distribution and prognostic relevance显示文摘 | TORSELLO A GARUFI C COSIMELLI M | 2008 | EurJ Cancer2008，44，9： | 1 |
| 16 | Quality of life and chronotherapy显示文摘 | Pugliese P Garufi C Perrone M | 2002 | Chronobiology International2002，19，1： | 1 |
| 17 | Protective effect of Capparis spinosa on chondrocytes显示文摘 | Panico A M Cardile V Garufi F | 2005 | Life Sci2005，77，： | 1 |
| 18 | Phase Ⅲ trial comparing 4-day chronomodulated therapy versus 2-day conventional delivery of fluorouracil,leucovorin,and oxaliplatin as first-line chemotherapy of metastatic colorectal cancer:the European Organisation for Research and Treatment of Cancer C显示文摘 | Giacchetti S Bjarnason G Garufi C | | 0，，22： | 1 |
| 19 | Protective effect of Capparis spinosa on chondrocytes 显示文摘 | Panico A M Cardile V Garufi F | 2005 | Life Sci2005，77，20： | 1 |
| 20 | Randomized prospective clinical study comparing induced aberrations with IntraLase and Hansatome flap creation in fellow eyes显示文摘 | Dan B. Tran Melvin A. Sarayba Zsolt Bor Carrie Garufis Yi-Jing Duh Charles R. Soltes Tibor Juhasz Ron M. Kurtz | 2005 | Journal of Cataract & Refractive Surgery2005，，1： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员